Dr. Reddy's Laboratories FY25 Annual Earnings Summary

Launch of high-value products like Rituximab biosimilar in the US depends on FDA approval, which is uncertain and could be delayed.

The US FDA issued a Form 483 with seven observations at the CTO2 facility in Bollaram, Hyderabad. Management has responded but resolution timeline is uncertain.

Lenalidomide revenue is expected to decline significantly after September-October 2025 as volume restrictions end and competition intensifies.

Potential tariffs on pharmaceutical imports could impact margins; management is working with customers to ensure supply continuity but uncertainty remains.

Exclusivity ends in January 2026, leading to significant revenue decline; management expects to offset through growth in other segments but risk remains.

Pricing pressure in some key products partially offset volume gains in North America.

Increased freight rates due to Red Sea route issues and air shipments added tens of crores to costs.

SG&A jumped 28% YoY; analyst questioned if one-offs were included. Management attributed to investments and freight, but full-year guidance implies normalization.

Revenue from lenalidomide (Revlimid) is subject to confidential agreements and competitive pressures; management declined to provide specific guidance on future sales.

Russia business faces unfavorable forex movements; despite hedging, devaluation could impact reported revenues.

A product faced procurement constraints from contract manufacturers, leading to a ₹92 crore impairment; similar issues could affect other products.

The company received a complete response letter (CRL) on the API side for iron sucrose, delaying the expected launch.